The agency previously approved Gilenya, a disease-modifying therapy, for adults with relapsing forms of multiple sclerosis. The treatment may now also be used for children ages 10 and up with the same condition.
“We now finally have an FDA-approved treatment for children and adolescents with relapsing MS,” said Brenda Banwell, MD, chief of the division of neurology at Children’s Hospital of Philadelphia, who served as co-principal investigator in a clinical trial to support the pediatric approval. “Repeated relapses are more common in young people with MS than in adults, so this is heartening news for patients and their families.”
More articles on supply chain:
Meet the 10 participants in the US drone program
FDA issues EpiPen shortage alert: 6 things to know
A new pharma giant —Takeda acquires Shire for $62B
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
